| Firm |
Analyst |
| B. Riley |
Kalpit Patel, Pharm.D. |
| Bank of America |
Jason Gerberry |
| Barclays |
Gena Wang, Ph.D. |
| BMO |
Evan Seigerman |
| Citi |
Yigal Nochomovitz, Ph.D. |
| Cowen |
Tyler Van Buren |
| Evercore ISI |
Umer Raffat |
| Goldman Sachs |
Salveen Richter, CFA |
| Guggenheim |
Michael Schmidt, Ph.D. |
| Jefferies |
Maury Raycroft, Ph.D. |
| JMP Securities |
Silvan Tuerkcan, Ph.D. |
| J.P. Morgan |
Eric Joseph, Ph.D. |
| Jones Trading |
Soumit Roy, Ph.D. |
| Morgan Stanley |
Michael Ulz |
| Needham |
Ami Fadia |
| Oppenheimer |
Jay Olson, Ph.D. |
| Piper Sandler & Co. |
Swapnil Malekar, Ph.D. |
| Stifel |
Benjamin Burnett |
| SVB Leerink |
Andrew Berens, M.D. |
Mirati Therapeutics is followed by the analysts listed above. Please note that any opinions, estimates or forecasts
regarding Mirati Therapeutics's performance made by these analysts are theirs alone and do not represent opinions,
forecasts or predictions of Mirati Therapeutics or its management. Mirati Therapeutics does not by its reference
above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.